Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia-positive acute lymphoblastic leukemia by Martin, V. (Vanesa) et al.
doi: 10.1111/j.1349-7006.2008.00884.x Cancer Sci |  2008
© 2008 Japanese Cancer Association
Blackwell Publishing Asia
Methylation status of Wnt signaling pathway genes 
affects the clinical outcome of Philadelphia-positive 
acute lymphoblastic leukemia
Vanesa Martin,1 Xabier Agirre,2 Antonio Jiménez-Velasco,3 Edurne San José-Eneriz,2 Lucia Cordeu,2 Leire Gárate,2 
Amaia Vilas-Zornoza,2 Juan A. Castillejo,1 Anabel Heiniger,3 Felipe Prósper,2 Antonio Torres1 and Jose Roman-Gomez1,4
1Hematology Department, Reina Sofia Hospital, 14004-Cordoba; 2Hematology Department and Area of Cell Therapy, Clinica Universitaria, Foundation for Applied 
Medical Research, University of Navarra, 31008-Pamploma; 3Hematology Department, Carlos Haya Hospital, 29010-Malaga, Spain
(Received April 6, 2008/Revised May 8, 2008/Accepted May 11, 2008)
The clinical significance of aberrant promoter methylation of the
canonical Wnt pathway antagonist genes (sFRP1, sFRP2, sFRP4,
sFRP5, Wif1, Dkk3, and Hdpr1) and also putative tumor-suppressor
gene Wnt5a, belonging to the non-canonical Wnt signaling pathway,
was investigated in a large series of 75 patients with Philadelphia
chromosome-positive acute lymphoblastic leukemia by methylation-
specific polymerase chain reaction. At least one methylated gene
was observed in cells from 66% (49/75) of patients (methylated
group). Disease-free survival and overall survival at 9 years were 51
and 40%, respectively, for the unmethylated group and 3 and 2%,
respectively, for the methylated group (both P < 0.0001). Multivariate
analysis demonstrated that the Wnt methylation profile was an
independent prognostic factor predicting disease-free survival
(P = 0.007) and overall survival (P = 0.039). Abnormal DNA methylation
of promoter-associated CpG islands in the Wnt signaling pathway is
very common in Philadelphia chromosome-positive acute lympho-
blastic leukemia and potentially defines subgroups with distinct
clinical characteristics. (Cancer Sci 2008)
The vast majority of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) have a
poor outcome when treated with chemotherapy alone, leading
most investigators to favor allogeneic stem cell transplantation
(SCT) for patients in first remission.(1) Despite this overall
dismal prognosis, it has been reported that patients with classic
Ph+ ALL who receive extensively reinforced early chemotherapy
show long-term disease-free survival (DFS), suggesting that a
subset of Ph+ cases may be curable with intensive chemotherapy
without SCT.(2) However, specific risk markers that identify such
patients are unknown.
Our group has demonstrated that the methylation of cytosine
nucleotides in ALL cells is the most important way to inactivate
cancer-related genes in this disease. This epigenetic event can
help to inactivate tumor-suppressive apoptotic or growth-arresting
responses and has prognostic impacts in B- and T-ALL.(3,4) In
fact, we have recently reported that epigenetic regulation is
responsible at least in part for the activation of canonical Wnt
signaling in ALL.(5) We found that expression of the Wnt inhibitors
sFRP1, sFRP2, sFRP4, sFRP5, Wif1, Dkk3, and Hdpr1 was
downregulated due to abnormal promoter methylation in ALL
cell lines and this event was associated with constitutive activation
of the Wnt signaling pathway in ALL patients, as demonstrated
by upregulation of the Wnt target genes Wnt16, Fz3, Tcf1, Lef1,
and cyclin D1, and the nuclear localization of β-catenin. In addition,
we have also demonstrated that the putative tumor-suppressor
gene Wnt5a, belonging to the non-canonical Wnt pathway, is
silenced by methylation in ALL and associated with further
upregulation of cyclin D1 expression.(6) Interestingly, hyper-
methylation of the gene promoters of Wnt inhibitors and Wnt5a
was observed in Ph+ ALL-derived cell lines and was associated
with downregulation of gene expression as demonstrated by
restored gene expression after treatment with 5-Aza-2′-deoxycytidine
in these cell lines.(5,6) Taken together, these data provide a rationale
for the hypothesis that epigenetic disregulation of the Wnt
signaling pathway is a potential mechanism that contributes to
the pathogenesis and, probably, the clinical course of Ph+ ALL.
In the present study, we report that the methylation phenotype
of Wnt pathway genes is able to redefine the prognostic impact
of the Philadelphia chromosome in ALL patients.
Material and Methods
Patients. We studied 42 male and 33 female patients (total of 75)
with classical de novo Ph+ ALL who were enrolled in successive
multicenter studies of the ‘Programa para el estudio y tratamiento
de las hemopatias malignas’ (PETHEMA) Spanish study group.
All of these patients were referred to the Reina Sofia Hospital of
Cordoba, Spain, from January 1989 to December 2004. The
median age at diagnosis in the study population as a whole was
40 years (range 2–82 years). Of these patients, 12 were children
(median age 8 years; range 2–14 years) and 63 presented with
adult ALL (median age 46 years; range 19–82 years). The study
was approved by the Investigational Review Board at Reina Sofia
Hospital in accordance with the policies of the Department of
Health and Human Services. Informed consent was obtained
from the patient or the patient’s guardians. Diagnosis was
established according to standard morphological, cytochemical,
and immunophenotypic criteria together with Philadelphia
chromosome detection by cytogenetics or BCR-ABL transcript
detection by reverse transcription–polymerase chain reaction
(PCR). Patients were entered in ALL protocols for high-risk
patients of the PETHEMA group. No patient showed additional
chromosomal abnormalities. Forty-four patients relapsed. Twenty-
four patients received SCT (1 autologous, 23 allogeneic) in the
first (n = 14) or second (n = 10) complete remission (CR). There
are 13 patients currently alive. The clinical characteristics of the
patients are listed in Table 1.
Methylation-specific PCR. Bone marrow specimens were obtained
from all patients at the time of diagnosis. High molecular weight
DNA was prepared from mononuclear diagnostic marrow cells
using conventional methods, frozen at –80°C, and analyzed
retrospectively to assess the role of the methylation profile. In
all cases, the diagnostic bone marrow sample contained at least
70% blast cells. Aberrant promoter methylation of the sFRP1,
sFRP2, sFRP4, sFRP5, Wif1, Dkk3, Hdpr1, and Wnt5a genes
was determined by methylation-specific PCR after bisulfite
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treatment of DNA, as reported by Herman et al.(7) Primer
sequences of each gene for the unmethylated and methylated
reactions have been reported elsewhere.(5,6) ‘Hot start’ PCR was
carried out for 30 cycles consisting of denaturation at 95°C for
1 min, annealing at 60°C for 1 min, and extension at 72°C for
1 min, followed by a final 7-min extension for all primer sets.
The products were separated by electrophoresis on a 2% agarose
gel. Bone marrow DNA from healthy donors was used as a
negative control for methylation-specific assays. Human male
genomic DNA universally methylated for all genes (Intergen
Company, Purchase, NY, USA) was used as a positive control
for methylated alleles. Water blanks were included with each
assay. The results were confirmed by repeat methylation-specific
PCR assays after an independent bisulfite treatment.
Statistical analysis. For statistical purposes, Ph+ ALL patients
were classified into two different methylation groups according
to the numbers of Wnt pathway genes methylated: the non-
methylated group (no methylated genes) and the methylated
group (at least one methylated gene). This classification was
derived after statistical analyses showing that the prognosis of
patients with one to six methylated genes was similar with no
significant differences (data not shown). P-values for comparisons
of continuous variables between groups of patients were two-tailed
and based on the Wilcoxon rank sum test. P-values for
dichotomous variables were based on the Fisher exact test. The
remaining P-values were based on the Pearson χ2-test. Overall
survival (OS) was measured from the day of diagnosis until
death from any cause and was censored only for patients known
to be alive at last contact. DFS was calculated from the date
of first CR until the date of first relapse or the date of death in
first CR. Patients alive and still in remission at the last follow-
up examination were censored in the analysis. Patients who
underwent SCT were included but censored at the date of
transplant. Distributions of OS and DFS curves were estimated
by the method of Kaplan and Meier, with 95% confidence
intervals calculated by means of Greenwood’s formula. Com-
parisons of OS or DFS between groups were based on the log-rank
test. Univariate and multivariate analyses (logistic regression
model) were used to determine the factors associated with DFS
and OS. Stepwise modelling was carried out to screen potential
variables for inclusion in the final model. The entry criterion for
the multivariable Cox regression analysis was a P-value less
than 0.1 in univariate analysis. P-values of no more than 0.05
were taken as the threshold for statistical significance in the final
model. All relapse and survival data were updated in December
2007, and all follow-up data were censored at that point.
Results and Discussion
Frequency of promoter methylation in ALL. Among the 75 Ph+
ALL, the methylation frequencies (in descending order) were as
follows: 40% for Wnt5a; 23% for sFRP5; 21% for Dkk3; 20%
for sFRP1; 13% for Hdpr1; 13% for Wif1; 12% for sFRP4; and
5% for sFRP2. No methylated genes (non-methylated group)
were found in 26 of 75 patients (34%) whereas most ALL (49
of 75 [66%]) had methylation of at least one gene (methylated
group), ranging from one to six methylated genes.
Clinical outcome and promoter methylation profile. As shown in
Table 1, aberrant methylation was observed more frequently in
adults (73%) than in children (25%; P = 0.002). Among adults,
elderly patients (≥55 years) showed the same level of methylation
(76 vs 71%) as adolescents and young adults (<55 years).
However, other features, including the number of patients who
received SCT, were similarly distributed among both methylation
groups. Table 1 also details the relapse history, CR rates, and
mortality for patients included in the different methylation
groups. The CR rates of patients in the non-methylated and
methylated groups were 88 and 69%, respectively (P = 0.04),
suggesting that methylation profile correlates with response to
remission induction therapy. Moreover, patients in the non-
methylated group had a lower relapse rate than patients in the
methylated group (38 vs 69%; P < 0.001). Mortality rate was also
lower for the non-methylated group compared with the methylated
group (54 vs 98%; P < 0.001).
We analyzed the DFS among patients who achieved CR according
to the methylation profile. Estimated DFS at 9 years were 51 and
3% for the non-methylated and methylated groups, respectively
(P < 0.0001; Fig. 1a). The actual OS at 9 years calculated for all
leukemic patients was 40% for non-methylated patients and 2%
for methylated patients (P < 0.0001; Fig. 1b).
Table 1. Clinical characteristics and outcome of 75 Philadelphia-positive acute lymphoblastic leukemia patients according to Wnt methylation
status
Feature Non-methylated (n = 26) Methylated (n = 49) P-value
Age (n) 0.002
<15 years   9     3
≥15 years  17    46
<55 years  11    27
≥55 years   6    19
Sex (male/female) (n) 15/11 27/22 Not significant
White blood cells (n) Not significant
<50 × 109/L 16    25
≥50 × 109/L 10    20
Cell phenotype (n) Not significant
Pro-B  1     3
Pre-B  7     8
Common 16    37
Biphenotypic  2     1
Stem cell transplantation (n)  9    15 Not significant
Best response (n)
Complete remission 23    34 0.04
Relapse (n) 10    34 <0.001
Death (n) 14    48 <0.001
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A multivariate analysis of potential prognostic factors demon-
strated that the hypermethylation profile was an independent
prognostic factor in predicting DFS (P = 0.007) as well as OS
(P = 0.039; Table 2).
The paucity of Ph+ ALL long-term survivors has made it
difficult to recognize potential prognostic factors in order to
distinguish good-risk groups from poor responders. Two studies
have demonstrated that in patients with early steroid response or
showing a white blood cell count below 25 × 109/L the outcome
is better.(2,8) Moreover, variant forms of Ph+ chromosome or
complex translocations confer a better prognosis than does classic
rearrangement, whereas monosomy 7 is associated with dismal
outcomes.(9–12) However, the biological features of prognostic
importance are not easily available in classical Ph+ ALL.
Our present findings indicate that classic t(9;22) ALL is a
more heterogeneous disease than previously suspected, at least
from an epigenetic point of view. Our data show that methylation
in human Ph+ ALL cells participates in deregulation of the Wnt
signaling pathway by inactivation of its antagonists Dkk3,
sFRP1, sFRP2, sFRP5, Hdpr1, and Wif1 and also by activating
non-canonical signaling by silencing Wnt5a. Aberrant methylation
of CpG islands is quantitatively different in individual tumors
within the same tumor type, and this patient-specific methylation
profile provides important prognostic information in BCR-ABL-
positive ALL patients treated with the same therapeutic protocol
and with a long follow up. The presence in individual tumors of
epigenetic events that affect the Wnt pathway is a factor of poor
prognosis in this disease. Patients with methylation of genes had
a poorer DFS and OS than patients with no methylated genes.
Multivariate analysis confirmed that the methylation profile
was associated with a shorter DFS and OS. Therefore, Wnt
methylation profiling in BCR-ABL-positive ALL could provide
important clinical information for: (i) guiding the selection of
therapy; and (ii) providing a basis for developing novel therapies.
Currently, the optimal treatment of Ph+ ALL patients requires
the addition of BCR-ABL tyrosine kinase inhibitors, such as
imatinib. Combined with chemotherapy or as a single agent, it
can produce high rates of CR. All of our patients were included
in the protocol before the imatinib era, so the role of this therapy
in the context of Wnt methylation could not be evaluated.
However, our present results suggest that the use of demethylating
agents like decitabine and 5-aza-2′-deoxycytidine or specific
inhibitors of Wnt pathway therapies such as quercetin and
antagonists of the oncogenic Tcf–β-catenin complex may be a
useful therapeutic strategy in Ph+ ALL for whom SCT is either
not feasible or refused.
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